Impactful technology

December 2019


HelixBind awarded $4M of additional funding by CARB-X to continue development of RaPID diagnostic platform.

MARCH 2018


HelixBind awarded up to $2M from CARB- X to combat the rise of antimicrobial resistant pathogens.


HelixBind closes $3M in Series-A financing


HelixBind awarded a $2.0M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.

APRIL 2017

USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis


HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

MARCH 2016

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours.

JULY 2015

HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)

MARCH 2014

HelixBind closes $1.65M seed financing

Together we will change the way infections are treated, improve care, and save lives.